ArticleFrontiers in immunology2026
Kangxianhuanji formula and its component rutin ameliorate acute exacerbation of idiopathic pulmonary fibrosis by targeting GLUT1 to suppress HIF-1α-mediated glycolysis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a life-threatening condition characterized by uncontrolled inflammation and progressive fibrosis, with limited effective therapies. Kangxianhuanji Formula (KHF), a traditional herbal prescription, has been used clinically for AE-IPF, but its molecular mechanisms remain unclear. This study aimed to elucidate the pharmacological mechanisms and active constituents of KHF. Methods: A bleomycin-induced AE-IPF mouse model was established to evaluate the therapeutic effects of KHF using histopathology, immunofluorescence, and inflammatory assessments. Network pharmacology was applied to predict targets, followed by drug affinity responsive target stability (DARTS) to identify direct binding proteins. Quantitative proteomics was used to validate target-related protein expression and pathway changes Results: KHF markedly alleviated lung injury in AE-IPF mice, as shown by reduced collagen deposition, decreased levels of interleukin-1 beta (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and high mobility group box 1 (HMGB1), and suppression of abnormal proliferation of alveolar type II epithelial cells. Network pharmacology suggested involvement of glycolysis-related pathways, including PI3K-Akt and HIF-1α signaling. DARTS and proteomics consistently identified GLUT1 as a core target. KHF inhibited glycolytic reprogramming, reflected by reduced expression of GLUT1, HIF-1α, and hexokinase 2 (HK2), along with decreased lactate production. LC-MS/MS and molecular docking identified rutin as a key GLUT1-targeting compound, which was further confirmed by CETSA. In macrophages, rutin showed anti-inflammatory and anti-glycolytic effects, and co-treatment with STF-31 showed no additive effects, suggesting a GLUT1-dependent mechanism. Conclusion: KHF exerts anti-inflammatory and anti-fibrotic effects in AE-IPF, partly by modulating GLUT1-mediated glycolysis and regulating the GLUT1/HIF-1α axis, with rutin as a key bioactive component. These findings support the clinical application of KHF and highlight GLUT1-centered metabolic pathways as potential therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.